Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer
International Journal of Clinical Oncology · 2026-05 · 31 (5) · 878-889
DOI: 10.1007/s10147-026-03006-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 10.03.2026. Verfasst von Naoyuki Iwahashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. naoyuki@wakayam…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Circulating Tumor DNA, Biomarkers, Tumor. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Liquid biopsy using circulating tumor DNA (ctDNA) is a minimally invasive approach for detecting tumor-associated genomic alterations. Although ctDNA analysis has been widely explored in solid tumors, its application to cervical cancer remains limited. Cancer personalized profiling by deep sequencing (CAPP-Seq) enables sensitive ctDNA profiling via molecular barcoding and digital error suppression.
Methods
We evaluated the feasibility of ctDNA-based mutation profiling in cervical cancer using the CAPP-Seq platform by analyzing plasma samples from 38 patients.
Results
The cohort included three patients with stage I disease, nine with stage II, 19 with stage III, and seven with stage IV. Somatic gene alterations were detected in 33 of the 38 cases (87%), including squamous cell carcinoma (27/29 [93%]) and adenocarcinoma (6/9 [67%]). Non-synonymous mutations were identified in 23 patients (59%), with PIK3CA being the most frequently mutated gene [13/38 (34%)]. Copy number gains of EGFR , MET , and ERBB2 were observed in 24%, 11%, and 5% of cases, respectively. The median blood tumor mutational burden was 17.7 mutations/Mb, and 50% of the patients exhibited a hypermutated phenotype. In a subset of four patients who received concurrent chemoradiotherapy, longitudinal changes in ctDNA mutation profiles between pre- and post-treatment samples were associated with treatment response.
Conclusions
This study demonstrates the feasibility of ctDNA-based mutation profiling using CAPP-Seq in cervical cancer, with a high detection rate of tumor-associated genomic alterations across histological subtypes. ctDNA analysis may represent a minimally invasive approach for the molecular characterization and disease monitoring of cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan. naoyuki@wakayama-med.ac.jp.
- Department of Obstetrics and Gynecology, School of Medicine, Wakayama Medical University, 811-1 Kimiidera, Wakayama, 641-8509, Japan.
- Faculty of Medicine, Department of Genome Biology, Kindai University, Osaka, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Iwahashi, N., Noguchi, T., Sakai, K., Yahata, T., Nishioka, K., Fujino, M., Takeda, S., Suzuki, N., Nishio, K., & Ino, K. (2026). Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer. International Journal of Clinical Oncology, 31(5), 878-889. https://doi.org/10.1007/s10147-026-03006-1
Vancouver
Iwahashi N, Noguchi T, Sakai K, Yahata T, Nishioka K, Fujino M, et al. Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer. International Journal of Clinical Oncology. 2026;31(5):878-889. doi:10.1007/s10147-026-03006-1
BibTeX
@article{Iwahashi2026,
author = {Iwahashi, Naoyuki and Noguchi, Tomoko and Sakai, Kazuko and Yahata, Tamaki and Nishioka, Kaho and Fujino, Megumi and Takeda, Shinichiro and Suzuki, Nobuhiko and Nishio, Kazuto and Ino, Kazuhiko},
title = {Comprehensive circulating tumor DNA mutation profiling via CAPP-Seq liquid biopsy for cervical cancer},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {5},
pages = {878--889},
doi = {10.1007/s10147-026-03006-1}
}
EUVIMED